Remove 2003 Remove Marketing Remove Vaccine
article thumbnail

Women in Stem with Andrea Pfeifer

Drug Target Review

On my return to Europe, I took a position at Nestlé as Head of the Research Centre, where I led the scientific development of several highly innovative health promoting food products from laboratory to market. Then I was approached to co-found AC Immune in 2003. COVID-19 has shown the revolutionary impact of vaccines.

Disease 95
article thumbnail

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

The Pharma Data

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52
article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

Since these issues could occur during the investigational phase of clinical development as well as in the post-marketing setting—and product status could very well differ by country/region—ICH members determined that these guidelines should be developed to facilitate the exchange of information in both settings.

FDA 40
article thumbnail

Alex Gorsky to Serve as Executive Chairman and Transition Role.

The Pharma Data

Under Mr. Gorsky’s leadership, the Company has delivered exceptional financial performance, with its market capitalization growing from nearly $180 billion to more than $470 billion as the share price increased over 170%. “I

article thumbnail

CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis

The Pharma Data

The CHMP opinion is one of the final steps in the marketing authorisation procedure prior to approval by the European Commission. pneumonia and sepsis) occurred more frequently in patients receiving Benlysta; consider pneumococcal vaccination prior to initiation. About lupus nephritis. Younger children may be at increased risk.

article thumbnail

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

The Pharma Data

In contrast to other options for RSV under development, such as maternal vaccines, nirsevimab was designed to be administered at birth to infants born during the RSV season or at the season’s start for infants born prior to the season. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering.

Virus 40
article thumbnail

European Commission approves Benlysta for adult patients with active lupus nephritis

The Pharma Data

The EU marketing authorisation follows the recent approval for the similar expanded LN indication in the U.S. pneumonia and sepsis) occurred more frequently in patients receiving Benlysta; consider pneumococcal vaccination prior to initiation. Immunisation: Do not give live vaccines 30 days before, or concurrently with Benlysta.